Publications
Detailed Information
Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh, Koung Jin | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Miso | - |
dc.contributor.author | Park, Young Sik | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Chung, Doo Hyun | - |
dc.contributor.author | Kim, Young Whan | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2020-04-27T11:12:18Z | - |
dc.date.available | 2020-04-27T11:12:18Z | - |
dc.date.created | 2018-09-04 | - |
dc.date.issued | 2016-07 | - |
dc.identifier.citation | Clinical Lung Cancer, Vol.17 No.4, pp.245-252.e1 | - |
dc.identifier.issn | 1525-7304 | - |
dc.identifier.other | 49963 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165286 | - |
dc.description.abstract | Our study aimed to determine the role of serum neuron-specific enolase (NSE) in predicting epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) response in EGFR mutant non-small cell lung cancer (NSCLC). Patients with elevated serum NSE levels had significantly shorter progression-free survival (PFS) and overall survival (OS) after first-line EGFR TKI treatment. Our study suggests potential use of NSE for predicting EGFR TKI response and prognosis. Objectives: Our study aimed to determine the predictive and prognostic values of the serum neuron-specific enolase (NSE) level in patients who had non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and who had been treated with EGFR-tyrosine kinase inhibitors (TKIs). Materials and Methods: We retrospectively analyzed 151 patients who had NSCLC harboring EGFR mutations and had received either gefitinib or erlotinib as first-line treatment between 2005 and 2014. The serum NSE level was measured before initiation of EGFR-TKI treatment. Results: Of the 151 patients, 92 (60.9%) had elevated NSE levels (> 16.3 ng/mL). Patients with elevated NSE levels showed significantly shorter progression-free survival (PFS) after EGFR-TKI treatment than those with normal NSE levels (median PFS, 10.5 months vs. 15.4 months; P = .034). Multivariate analysis demonstrated that elevated NSE levels (hazard ratio [HR], 1.656; P = .017), CNS metastasis at diagnosis (HR, 1.567; P = .037), and male gender (HR, 1.840; P = .005) were independent predictive factors for short PFS. A significant difference in overall survival (OS) was observed between patient groups with elevated and normal NSE levels (median OS, 17.0 months vs. 29.1 months; P < .001), and serum NSE level remained an independent prognostic factor for OS in multivariate analysis (HR, 2.671; P < .001). Conclusion: Patients with elevated serum NSE levels have significantly shorter PFS and OS. The NSE level is both a predictive marker of EGFR-TKI treatment and a prognostic marker in EGFR-mutant NSCLC patients. (C) 2015 Elsevier Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.publisher | Cancer Information Group | - |
dc.title | Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 전윤경 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 정두현 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 김영환 | - |
dc.identifier.doi | 10.1016/j.cllc.2015.11.012 | - |
dc.citation.journaltitle | Clinical Lung Cancer | - |
dc.identifier.wosid | 000378616200003 | - |
dc.identifier.scopusid | 2-s2.0-84950341986 | - |
dc.citation.endpage | 252.e1 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 245 | - |
dc.citation.volume | 17 | - |
dc.identifier.sci | 000378616200003 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Chung, Doo Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Young Whan | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CLAMP-BASED TEST | - |
dc.subject.keywordPlus | NEUROENDOCRINE DIFFERENTIATION | - |
dc.subject.keywordPlus | TUMOR-MARKER | - |
dc.subject.keywordPlus | CLINICAL-APPLICATIONS | - |
dc.subject.keywordPlus | PROGNOSTIC VALUE | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | NSE | - |
dc.subject.keywordPlus | TRANSFORMATION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordAuthor | NSE | - |
dc.subject.keywordAuthor | Predictive value | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Progression-free survival | - |
dc.subject.keywordAuthor | Tumor heterogeneity | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.